Vaccine-maker Bharat Biotech claimed that with several hundred million doses administered worldwide, Covaxin has demonstrated an excellent safety record with minimal adverse events and no vaccine associated cases detected for myocarditis or thrombocytopenia
Indian pharmaceutical company Zydus said on Wednesday it has started human studies for its potential COVID-19 vaccine, as coronavirus infections continue to surge in the world’s third worst-hit nation.
ZyCoV-D, its plasmid DNA vaccine, was found to be safe, immunogenic and well-tolerated in the pre-clinical toxicity studies, Zydus said.
In the human trials, Zydus will enrol over 1,000 subjects across multiple clinical study sites in India.
Delhi’s air may be growing more toxic by the day — but on Sunday, authorities appeared to view a peaceful…
The 14th State Level Philatelic Exhibition, MAPPEX-2025, organized by the Madhya Pradesh Postal Circle, was held in Bhopal from November…
South Asia accounts for 50% of the groundwater pumped for irrigation globally. The practice has been critical to ensuring food…
Earlier this week, news came in that ousted Bangladesh Prime Minister Sheikh Hasina has been sentenced to death – by…
At the 14th edition of the Dharamshala International Film Festival, three documentaries stood out for the way they portrayed the…
The Special Intensive Revision of the voters list across 12 Indian states could potentially lead to sharpening of the communal…
This website uses cookies.